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ABSTRACT 
 
The transporters primarily responsible for transporting important nutrients involved in 
energy metabolism have a wide substrate specificity setting up the potential for drug-nutrient 
transporter interactions. Pharmacological inhibition of nutrient transport across the lactating 
mammary and neonatal intestinal epithelial barrier can directly and indirectly affect growth and 
maturation of the developing neonate by either reducing the uptake of important nutrients by the 
neonate or by disrupting epithelial barrier integrity. My thesis focused on two transporters, 
OCTN2 and MCT1, expressed in immortalized intestinal and mammary epithelial cell cultures to 
assess the effects of their pharmacological inhibition on L-carnitine and butyrate flux, 
respectively, and polarized epithelial barrier integrity. 
Human colorectal adenocarcinoma (Caco-2) and bovine mammary (BME-UV) cell lines 
were grown into monolayers on 12-well tissue culture plates and subsequently exposed to the 
presence or absence of OCTN2 and MCT1 inhibitors for 6, 12, and 24 hours as well as 7 days. 
Failure to obtain a polarized mammary monolayer prevented the analysis of the direct effects of 
nutrient transport inhibition on nutrient flux forcing the focus on the indirect effects. To assess 
polarized epithelial barrier integrity, transepithelial electrical resistance and Lucifer yellow 
rejection rates were measured at each time point. No trend was noted between control and treated 
groups. To assess the acute and chronic effects of pharmacological exposure on polarized 
epithelial function, a limited appraisal of nutrient transporter expression and cellular homeostasis 
parameters was conducted. Following exposure at each time point, mRNA expression of 
OCTN1, OCTN2, MCT1, MCT2 and GADPH were measured using qPCR. Low mRNA yields 
resulted in an inability to assess transporter expression levels in the epithelial systems. Cellular 
homeostasis parameters were analyzed using the CellTiter-Glo Luminescent Cell Viability 
Assay, pH-Xtra Glycolysis Assay and MitoXpress Xtra Oxygen Consumption Assay. These 
assays measured ATP synthesis, glycolytic flux and cellular respiration, respectively. No 
significant trend was noted in ATP synthesis between control and treated groups. An upward 
trend in both glycolytic flux and cellular respiration was noted in treatment with both inhibitors 
in both cell lines.  
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Complications in obtaining polarized monolayer forced the focus on the indirect affects, 
therefore, obtaining and utilizing a more accurate portrayal of the lactating mammary and 
neonatal intestinal epithelium is critical in answering this research question as both of these 
systems are highly synthetic and complex. By doing so, a more accurate representation of the 
effects of pharmacological inhibition of nutrient transporters essential for energy metabolism can 
be identified. 
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1. INTRODUCTION 
 
Maintenance of polarized epithelial barrier integrity is essential to ensure a polarized 
phenotype as well as vectorial transport across the membrane. Although many factors are 
required to maintain barrier integrity, essential nutrients are critical to maintain epithelial cell 
homeostasis. Membrane transporters ensure the availability of a variety of nutrients to the 
epithelial cell, however, these nutrient transporters also transport drugs and other xenobiotics 
across the membrane. Consequently, a high potential exists for drug-nutrient transport 
interactions to occur resulting in a loss of nutrient availability with potential concomitant loss of 
polarized epithelial function and integrity. Such interactions may have clinical relevance and 
may also identify another potential toxicological mechanism to explain adverse drug reactions. 
For example, loss of epithelial function through a decrease in nutrient availability may result in 
disease pathogenesis as noted in Inflammatory Bowel Disease (IBD), or loss of secretion as seen 
in the lactating mammary gland. The intestinal and lactating mammary epitheliums are two 
epithelia whose primary function is to assure nutrient availability and maintenance of health and 
normal development, yet have differing cellular energy requirements. My thesis research intends 
to address the consequences of xenobiotic-nutrient transporter interactions with a focus on 
nutrients essential for energy metabolism within epithelia that rely on different energy 
metabolism pathways in the hope of identification of a toxicological mechanism of action not 
generally appreciated in the literature. Furthermore, my thesis research is premised in the 
ongoing investigations in my lab involving the lactating mother-neonate dyad and the 
toxicological risk to the nursing neonate following drug/disease interactions in the medicated 
mother. 
My thesis specifically focuses on the essential nutrients, L-carnitine and butyrate. These 
nutrients are not only required for development of the neonate, but also the maintenance of 
epithelial barrier integrity and function. The mammary and intestinal epithelium represent 
complex barriers separating compartments of different compositions and the integrity and proper 
functioning of these barriers is critical to the provision of adequate nutrition to the neonate. L-
Carnitine has an important role in mitochondrial utilization of long chain fatty acids for energy 
metabolism and butyrate represents an important energy source for colonic cells and is involved 
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in epigenetic regulation. Both nutrients require carrier mediated transport into the epithelial cell 
and adequate cellular availability of these nutrients is critical to ensure proper barrier integrity 
and the maintenance of polarized epithelial function. Furthermore, the transporters involved in 
the uptake of L-carnitine and butyrate also include in their substrate profiles numerous 
xenobiotics. This creates a potential for significant drug-nutrient transporter interactions to 
occur. Therefore, in my thesis I evaluate the inhibition of transporter mediated uptake of the 
essential nutrients, butyrate and L-carnitine, and the effects on epithelial barrier integrity as a 
proof of concept investigation to represent the plausible effects that can occur in the medicated 
nursing mother-neonate dyad, i.e. loss of epithelial barrier integrity and function of the intestine 
and/or mammary gland can have detrimental effects on the provision of nutrition to the neonate 
and overall neonatal health and development. 
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2. LITERATURE REVIEW 
 
2.1 Lactating Mother-Neonate Dyad 
Following birth, neonates are required to rapidly adjust from the intrauterine to the 
extrauterine environment. One of the major adaptations required is the switch of nutrition from 
umbilical blood to milk supplied from the lactating mother. This sets up a complex and dynamic 
unit and interchange between the mother and child to allow the neonate to receive the essential 
nutrients required for proper growth and development. In the exclusively breastfed neonate, the 
mammary epithelium must assure adequate availability of all essential nutrients while the 
neonatal intestinal system must function adequately to absorb these essential nutrients for 
appropriate growth and maintenance of neonatal health.  Any disruption to the availability of 
nutrients by the maternal mammary gland or the absorbance of the nutrients at the neonatal 
intestinal gland may adversely impact the health and development of the breastfeeding neonate. 
 
2.2 Importance of Breastfeeding 
Breastmilk is the biological and natural way to feed infants versus the synthetic substitute 
of formula. Exclusive breastmilk feeding for the first 6 months of life, with continued feeding for 
1-2 years has become the recognized standard for infant feeding (1). Breastmilk has many 
benefits over its formula substitute including containing the essential components required by the 
neonate to adapt to the post-natal world. Breastmilk contains a number of nutrients  required for 
growth and development and also provides protection from infections and immune mediated 
disease and also allows the infant’s own immune system to mature (2). The majority of diseases 
with an immune component in their etiology have a lower incidence rate in breastfed infants 
compared to formula fed infants (3). Further, breastmilk’s functional components uniquely adapt 
to the changing needs of the neonate to support growth making it far superior to formula. 
 
2.2.1 Changes in Milk Composition with Time to Meet Neonate Requirements 
Human milk is a complex fluid that uniquely adapts to the needs of the developing 
neonate. After parturition, the requirements of the neonate are constantly shifting and the 
components of milk mirror that shift with changes to meet these requirements. The initial milk to 
be secreted, colostrum, is produced in low quantities and is predominated by growth factors and 
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immune protective proteins due to the neonate’s naïve and immature immune system. Colostrum 
also contains low concentrations of lactose representing it’s primary function as immunologic 
rather than nutritional (1). As lactation continues, the concentration of these proteins decreases, 
and casein (source of amino acids), increases (3).   
The first notable change to occur in the milk composition following parturition is an 
increase in lactose concentration and a decrease in sodium and chloride concentrations (4). This 
comes following the closure of tight junctions of the mammary epithelium to allow the volume 
of milk to grow within the lactiferous ducts. With the closure of the tight junctions at the 
mammary gland epithelium, lactose can no longer pass between the epithelial cells into the 
maternal blood, and sodium and chloride can no longer pass from the interstitial space into the 
lumen of the gland. The next change noted is an increase in the concentration of protective 
proteins, such as secretory immunoglobulin A (sIgA) and lactoferrin (5). The concentration of 
these proteins remain high for 2 days postpartum and then decrease rapidly due to dilution by the 
increased volume of secreted milk (5). The increase in milk secretion is also accompanied by an 
increase in the rates of synthesis and secretion of the majority of milk components including 
lactose, casein, calcium, sodium, magnesium and potassium (6). This allows the milk to provide 
nutrients with high bioavailability and in sufficient quantities to support the growing needs of the 
developing neonate. 
The nutritional components of human milk, either macronutrients or micronutrients, derive 
from 3 sources: synthesis in the lactocyte, dietary, and from maternal stores  (1). Macronutrient 
composition is conserved compared to micronutrients, however, can differ between preterm and 
term milk with preterm milk being higher in protein and fat (1). The proteins in human milk are 
divided into two fractions, whey and casein, each with a specific array of proteins and peptides 
with the most abundant being casein, α-lactalbumin, lactoferrin, sIgA and lysozyme (7). Fat is 
the most variable macronutrient and is characterized by high contents of palmitic and oleic acids 
in varying positions of the triglycerides (1). The primary sugar found in human milk is 
disaccharide lactose and is the least variable in concentration among the macronutrients (8). The 
micronutrients in human milk, including vitamins A, B1, B2, B6, B12, and D, and iodine, are far 
more variable and may depend on maternal diet and body stores (1) 
Concentrations of certain micronutrients, including L-carnitine, have been shown to vary 
over the course of lactation correlating to the changing expression of transporters. Our laboratory 
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challenged L-carnitine transporters with inflammatory agents and noted an increase in maximal 
activity (Vmax) of L-carnitine transport without an effect on the affinity (Km). This corresponded 
to changes in mRNA expression of the OCTN2 transporter (previously reported in our 
laboratory) and to changes in cellular energy levels and oxygen consumption rates (Uma 
Manthena MSc Thesis).  
Changes in transporter expression has been shown to vary depending on the duration of 
lactation corresponding with the needs of the developing neonate at that time (9, 10). Five 
distinct patterns have been shown: 1) decreasing throughout lactation (OCTN2), 2) prominent 
increase in early lactation, which may remain elevated or decline with advancing lactation 
(OCTN1), 3) constant but decreasing later in lactation (OCTN3), 4) increasing until mid-to-late 
lactation (OCTN1), 5) prominent increase late in lactation (Ncbt1) (10). The varying expression 
of OCTNs allow for a greater drug-nutrient interaction involving L-carnitine resulting in 
significant differences in milk-serum ratios of L-carnitine (9). 
 
2.2.2 Role of Milk in Neonatal Health 
Neonates are developmentally immature at birth and rely solely on the mother’s milk 
supply to aid them in the transition to the post-natal world. The complex fluid is an intrinsic 
mixture of bioactive proteins, lipids and carbohydrates that allows for the stimulation of cellular 
growth, digestive maturation, establishment of symbiotic microflora, and the development of gut 
lymphoid tissues (3).   
The nutritional composition in human milk, both macronutrients and micronutrients, are 
designed for host defense, antimicrobial protection, and stimulation of immunocompetence (3). 
Lactoferrin, a major protein found in breast milk, chelates free iron increasing the rate of 
absorption of iron by the infant. This key protein also inhibits the pathobiology of several 
bacteria (11), stimulates phagocytosis of pathogens (12), and inhibits human immunodeficiency 
virus (13). The large fat (triglyceride) content in breast milk also aids in development. Upon 
digestion, the triglycerides are converted into free fatty acids and monoglycerides which inhibit 
viruses, some bacteria and protozoans (14). IgA exists in concentrations around 1 g/L in breast 
milk and helps with the inhibition of infection by enteric pathogens (15). This antibody is not 
digested fully allowing accumulation in the intestine to occur where it binds to antigens 
rendering the pathogen less infective (15).  
6 
 
Beyond maturation of the GI tract, the multifunctional role of breast milk provides the 
tools for the successful development of the neonate. The lipids in the breast milk are vital for 
neonatal growth and development as they provide a dense energy source as well as essential fatty 
acids such as docosahexaenoic acid (DHA) (16). Though various lipids are the major energy-
yielding substrates in breast milk, carbohydrates also provide energy for the newborn, and are 
essential for central nervous system kidney, brain, muscle (including the heart) function (17). 
The micronutrients can modify hormones, growth factors and cell signaling pathways, with 
subsequent effects on development during early life (18). For example, milk contains 
erythropoietin (Epo), the primary hormone responsible for increasing red blood cells (RBCs). 
This is critical as blood loss, intestinal pathology, and immaturity of the hematopoietic system 
contribute to anemia in premature infants, which can drastically affect growth and development 
(1). 
 
2.3 Role of Mammary and Intestinal Epithelium in Neonatal Nutrition 
 The mammary and neonatal epithelial systems work in concert to ensure the neonate 
receives proper nutrition. The mammary gland, through a process called lactogenesis, becomes 
sufficiently differentiated to synthesize and secrete milk. With nursing, the intestinal epithelium 
of the neonate is responsible for the absorption of the essential nutrients found within the milk 
that are critical for the proper growth and development of the neonate. Both the availability of 
the nutrients to the lactating mammary epithelium and the absorption of nutrients at the intestinal 
epithelium rely on a proper functioning epithelial system. 
The main role of the polarized epithelium is to act as a selective barrier that regulates the 
composition of opposing compartments and to maintain homeostasis. Achievement of these 
functions is dependent upon a surface membrane that is organized into structurally, 
biochemically and physiologically distinct domains (apical and basolateral) containing specific 
ion channels and transport proteins (19). Epithelial cell membranes compose the majority of the 
barrier and are largely impermeable to hydrophilic solutes except where transporters are present. 
The domain facing the luminal compartment, the apical domain, is lined with specialized 
proteins that depict the main function of the cell (ie: absorption or secretion) (19). The 
basolateral membrane faces the extracellular compartment and contacts adjacent cells and has 
specialized junctions as well as cell adhesion structures (20). These junctional complexes are 
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essential in the role of maintaining a polarized phenotype within the epithelial cells and ensuring 
vectorial transport across the membrane (19, 20). 
The apical junctional complex (AJC) allows for the separation of the apical and basolateral 
domains and is an essential signaling center critical to the function of the polarized epithelium 
(20). Tight junctions, a particularly important part of the AJC, create the barrier between the 
apical and basolateral surface as well as between adjacent cells limiting paracellular transport 
and promoting transcellular transport. Transcellular transport from one side of the epithelium to 
the other occurs mainly through passive diffusion and carrier mediated transport but can also be 
the result of endocytosis and exocytosis (together coined transcytosis). Transport via this 
mechanism is directional, energy dependent, and governed by cell-specific transporters and 
channels positioned either on the apical or basolateral membrane (21) and is also the primary 
route that nutrients transverse the epithelial barrier. 
Proper function of the polarized epithelium is critical to regulate the compositions of the 
luminal and extracellular compartments. If barrier integrity of the epithelium becomes 
compromised, paracellular transport will become more prominent leading to altered composition 
of the opposing compartments resulting in a disruption in homeostasis. Due to the highly 
regulated and synthetic nature of these two epithelial systems, any disruption to cellular energy 
homeostasis can, in turn, lead to impaired barrier integrity. In particular, adenosine triphosphate 
(ATP) synthesis and oxygen consumption are two factors that are critical for the regulation of 
cellular energy homeostasis and the maintenance of the mammary and intestinal epithelial barrier 
(22). 
 
2.3.1 Lactating Mammary Epithelium 
The lactating mammary gland is a complex network of ducts formed of epithelial cells 
ending in lubulo-alveolar clusters, which are ultimately the site of milk secretion (23). Each 
alveolus is surrounded by a monolayer of polarized epithelial cells which is in turn surrounded 
by myoepithelial cells that aid in the function of milk secretion (23). The mammary epithelium is 
responsible for the synthesis of or availability of many of the milk constituents, making it one of 
the most highly synthetic tissues of the body. Due to the high activity of these cells, a large 
amount of energy is required. The main metabolic pathway utilized by the lactating mammary 
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gland is glycolysis; the conversion of glucose into pyruvate allowing free energy in the form of 
ATP to be released (24).  
 
2.3.1.1 Lactogenesis 
Lactogenesis, the initiation of lactation, is a complex process that represents numerous 
changes in the activity of differentiated mammary epithelial cells from inactive non-secretory 
state to an active secretory state (25). Lactogenesis begins around mid-pregnancy in most 
species, including humans, and has been divided into two phases: Initiation phase and activation 
phase based on differences in the composition of the secretions, expression of genes, and 
structural and functional properties of the cells (23, 26)  
The initiation phase (lactogenesis I) occurs during pregnancy when the mammary gland 
becomes sufficiently differentiated allowing the alveolar cells the capability to secrete small 
amounts of specific milk components including α-lactalbumin and lactose, which in humans, can 
be detected in the plasma and urine (27) This stage of lactation is characterized by an increased 
expression of milk protein genes, biosynthetic enzymes, as well as an accumulation of neutral 
lipid droplets (26). The mammary gland is sufficiently differentiated to secrete milk following 
completion of this phase, but milk secretion is prevented by high plasma concentrations of 
progesterone (28). 
 Copious secretion of milk occurs during the activation phase of differentiation 
(lactogenesis II) which after parturition in humans (23). This phase is characterized by induction 
of additional milk protein genes and enzyme expression, polarization of organelles, expansion of 
mitochondria and rough endoplasmic reticulum, and maturation of the Golgi apparatus (26, 29). 
These drastic changes, accompanied by the closure of the tight junctions, occurs during the first 
4 days following birth allowing the infant to receive 500-750 mL of milk per day by day 5 (6). 
The secretion during lactation is a complex mixture coming from different secretory 
pathways across, within, and also between mammary epithelial cells (30). There are five major 
routes of secretion across the lactating mammary epithelium from the blood side to milk, four 
transcellular and one paracellular: 1) membrane route, 2) golgi route, 3) milk fat route, 4) 
transcytosis, and 5) paracellular route (31). Transport across the lactating mammary epithelium is 
mainly attributed to transcellular transport, however, there are times when a significant flux 
occurs via the paracellular route such as during pregnancy (30).  
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2.3.2 Intestinal Epithelium 
The intestinal epithelium is the largest mucosal surface in the human body with the key job 
of protecting an individual from the external environment and providing nutrients to sustain life 
(32). The epithelium forms a selectively permeable barrier that separates contents of the 
intestinal lumen from the interstitium while maintaining body homeostasis (33). The epithelial 
cells form an effective barrier to the majority of hydrophilic solutes, however, the paracellular 
space must also be considered for an intact barrier (33). Paracellular permeability of the 
intestinal epithelium depends on the dynamic regulation of tight junctions. Due to the diverse 
challenges the intestinal epithelial barrier is subjected to, the tight junctions must be capable of 
rapid and complex responses (32). 
Due to the complex and active nature of the intestinal epithelium, high amounts of energy 
are required. The main energy source for colonic cells is β-oxidation of short chain fatty acids 
derived from bacterial carbohydrate fermentation (34). Acetate, propionate, and butyrate are the 
three main acids with butyrate being the preferred fuel accounting for about 70% of total energy 
consumption (34). Absorption of short chain fatty acids across the apical membrane is 
concentration dependent with no saturation and is coupled with sodium absorption (35). Much 
like the mammary gland, the small intestine makes use of glucose for energy requirements (36). 
Primarily, glucose is utilized via the glycolytic pathway with less than 5% of the glucose 
utilization occurring via the pentose phosphate pathway (36). 
 
2.3.2.1 Neonate’s Intestine 
At the time of birth, the neonate’s gastrointestinal (GI) tract is underdeveloped and 
immature. Following parturition, there is a period of drastic changes in the neonate’s GI tract. 
Mucosal immunity begins to develop in utero and continues from birth to early childhood. The 
intestine undergoes significant growth and adaptation to exogenous and endogenous stimuli in 
response to feeding (37). Nutritional components as well as stimuli from the microenvironment, 
including the gut microbiome, help to regulate and develop the immune response within the 
intestine (37). Human milk is designed to aid in host defense, antimicrobial protection, and 
stimulation of immunocompetence (3).  Breast milk feeding allows the neonatal intestine to be 
exposed to the protective anti-inflammatory nutrients required until the developing infant can 
synthesize its own anti-inflammatory mechanisms (2). 
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2.4 Nutrients 
Numerous nutrients are required for the proper development of the neonate and 
maintenance of normal body function. Some nutrients, however, are more critical than others and 
can, therefore, be divided into three categories: essential, conditionally essential, and non-
essential. The essentiality of a nutrient signifies that is has an indispensable physiological 
function, and when withdrawn from the diet, results in implications in growth and development 
and sometimes illness (38). An essential nutrient cannot by synthesized endogenously at an 
adequate rate by a healthy individual and, therefore, must be received by diet (38). A nutrient is 
considered ‘conditionally essential’ when there is a critical physiological function and it is 
nutritionally nonessential for normal subjects, however, synthesis is rate-limited (such as in the 
immature neonate) or lost in certain individuals (38, 39). Nutritionally nonessential nutrients can 
also serve key physiological functions but they can be synthesized at a sufficient rate such that 
dietary withdrawal causes no adverse effects (38). 
 
2.5 Carrier-Mediated Transport of Nutrients across the Epithelium 
The majority of nutrients utilize carrier-mediated transport to transverse the epithelia. 
This transcellular mechanism makes use of membrane proteins that act as vectorial transporters 
across the epithelium. Compared to passive diffusion, much greater levels of transport are 
achieved through carrier-mediated mechanisms. Unlike passive diffusion, a carrier-mediated 
mechanism is subject to saturation as well as inhibition. Inhibition, a result of a competitive or 
non-competitive interaction with another compound, has the potential to prevent the transport of 
the desired compound. This can lead to a disruption in the cellular homeostasis inadvertently 
leading to a disruption in barrier integrity. 
 Transporters can generally be divided into two classifications; uptake transporters and 
efflux transporters, with both being essential for the maintenance of homeostasis and barrier 
integrity. Uptake transporters are required for the cellular entry of compounds and are generally 
noted by members of the solute carrier (SLC) super family of transporters (40). Efflux 
transporters require energy to export compounds out of the cell due to the transport often being 
against a concentration gradient (40). The majority of efflux transporters are members of the 
ATP-binding cassette (ABC) superfamily and utilize binding and hydrolysis of ATP to function 
and mediate transport (40). To fully understand the disposition of nutrients, consideration of the 
11 
 
complex interplay between uptake and efflux transporters within a given epithelium must be 
given due to the possibility of nutrient movement being either impeded or facilitated by the 
existence and localization of transporter proteins at either domain (40). 
 
2.5.1 ATP-Binding Cassette Transporter Superfamily 
The ATP-Binding Cassette (ABC) superfamily has been divided into seven sub-families 
with 49 known human ABC genes, 48 which are functional (41). ABC Transporters are mainly 
responsible for the efflux of substrates via an active, ATP-dependent manner against dynamic 
concentration gradients (42). This family of transporters contain a pair of ATP-binding domains 
(nucleotide binding folds (NBFs)), and two sets of transmembrane domains, and typically 
contain six membrane-spanning α-helices (43). The localization of these transporters is primarily 
in the plasma membrane, where they export a variety or structurally diverse drugs, conjugates 
and metabolites as well as other compounds from the cell (42). Members of the ABC transporter 
family have become a critical defense mechanism limiting exposure to cells to toxic xenobiotics 
(40). These efflux transporters account for the removal of a wide variety of compounds including 
phospholipids, steroids, polysaccharides, peptides, amino acids, ions, organic anions, bile acids, 
drugs and other xenobiotics (41) 
 There are three classes of ABC transporters; P-glycoprotein (P-gp; ABCB) family, 
multidrug-resistance associated (MRP; ABCC) protein family, and the breast cancer resistance 
(BCRP; ABCG) protein family (40). The P-gp transporters consist of two similar halves, each 
containing six transmembrane segments and an intracellular ATP binding site (42). MRP 
transporters have a similar architecture at the P-gp family with the addition of an N-terminal 
extension (42). The BCRP transporter family is the most recently discovered, and unlike the 
others, is a half transporter with only a single N-terminal, intracellular ATP binding site, and six 
transmembrane segments (42). 
 
2.5.2 Solute Carrier Transporter Superfamily 
The Solute Carrier (SLC) transporter superfamily is by far the largest group of transporters 
with 55 sub-families with at least 362 known SLC genes with 20-25% amino acid sequence 
shared by member proteins belonging to the same SLC gene family (44). Members of this 
transporter superfamily have varied biochemical properties and include passive transporters, 
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active transporters, as well as mitochondrial and vesicular transporters (44). Active transporters 
couple the movement of one molecule against its concentration gradient, to the gradient of 
another molecule, while passive transporters only transfer molecules along their own 
concentration gradient (44, 45). Localization within the cell varies depending on the type of 
transporter being considered. The majority of SLC transporters are localized to the plasma 
membrane while others are located in the mitochondria (46), peroxisomes (47), and synaptic 
vesicles (48). 
 
2.5.2.1 Organic Cation-Carnitine Transporters  
Organic Cation-Carnitine Transporters (OCTNs) belong to the SLC22A family of 
transporters and are widely expressed in mammalian tissues. Three types of OCTNs have been 
identified; OCTN1, OCTN2, and OCTN3. The first discovered, OCTN1, showed similar 
structure to organic cation transporters (OCTs) and organic anion transporters (OATs), and 
transports organic cations (49). The second member, OCTN2, is a Na
2+
-dependent transporter 
and has the ability to interact with a variety of cations including L-carnitine, an essential nutrient 
involved in β-oxidation of long chain fatty acids (50). This transporter is critical for the 
movement of L-carnitine as it is the primary transporter that mediates the Na
2+
-independent 
transport of this essential nutrient (51). OCTN2 has been identified as the gene responsible for 
inherited primary systemic L-carnitine deficiency as it is essential for the reabsorption of L-
carnitine that has been filtered through the glomerulus across renal epithelial cells (52). OCTN3, 
the third member of the family, has specific activity for L-carnitine only (53). The OCTNs, 
although very similar in amino acid sequences, have distinct functional binding sites allowing 
them to discriminate against other substrates. However, OCTN2 may have multiple universal 
binding sites as it accepts both L-carnitine and other organic cations (53).  
 
2.5.2.2 Monocarboxylate Transporters 
Monocarboxylate Transporters, responsible for the uptake of monocarboxylates into 
epithelial cells, can be classified into two types; proton-coupled monocarboxylate transporters 
(MCTs) and Na
2+
-coupled monocarboxylate transporters (SMCTs). There are 14 members of the 
MCTs (MCT1-14) which belong to the SLC16A family of transporters. The MCTs are 
responsible for the transport of short-chain monocarboxylates such as lactate, pyruvate, and 
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butyrate for production of long chain fatty acids. Further, and more critical, MCT1 transports 
ketone bodies and SCFAs from cell cytosol to mitochondria for the production of cellular 
metabolic energy  (54). MCT1 has been shown to be the primary transporter for butyrate, a short 
chain fatty acid responsible for up to 70% of colonic energy supplies (54). Any alteration in the 
expression of MCT1 would decrease the intracellular availability of butyrate drastically affecting 
cell regulatory effects (55).  
 
2.6 Drug-Nutrient Transporter Interactions 
Drug-nutrient transporter interactions are defined as any physical, chemical, physiologic, 
or pathophysiologic relationship between a drug and a nutrient transporter (56). Drug induced 
inhibition of nutrient transporters, such as MCT1 and OCTN2, is increasingly being recognized 
as an important toxicological mechanism due to the severe consequences related to such 
interactions (9, 57). This is exemplified by the recent identification of inhibition of bile salt 
excretory protein (BSEP) as a significant cause of drug induced liver injury (58). Numerous 
drugs can interfere with normal bile formation resulting in cholestasis in the mammalian liver 
which is characterized by pruritus, jaundice caused by hyperbilirubinemia, altered lipid and 
cholesterol metabolism, and intestinal malabsorption of fat and fat soluble vitamins (58). Chronic 
conditions result in biliary cirrhosis due to bile salt-induced toxic liver cell necrosis leading to 
fibrosis and cirrhosis (58). Due to the serious adverse effects associated with BSEP inhibition, 
several drugs have been withdrawn from the market leading to the inclusion of BSEP inhibition 
potential by the Pharmaceutical Industry in their drug discovery toxicological screening assays. 
 
Inhibition of nutrient transporters has the potential to decrease nutrient availability to the 
epithelium and, in turn, result in the epithelium not operating optimally. Without proper 
management or recognition, these interactions may lead to treatment failure, toxicity and 
sometimes fatal adverse effects. This is especially exemplified when considering the inhibition 
of essential nutrients that are required by the developing neonate. Due to the many substrates 
associated with key nutrient transporters there is a high potential for drug-nutrient interactions to 
occur that may have clinical relevance. Drug-nutrient interactions have been well documented in 
many systems including the GI tract, kidney and liver while some areas, including the mammary 
gland, have received limited attention (59). 
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2.6.1 Interactions at the Mammary Epithelium 
Interactions at the lactating mammary epithelium has the potential to lead to numerous 
adverse effects including the disruption of milk volume and composition, affecting the blood 
flow to the mammary gland, or through direct/indirect interference with nutrient secretion (60). 
Nutrient secretion across the mammary epithelium into the milk space is essential as the milk is 
often the sole source of many nutrients required by the developing neonate. Any disruption to 
nutrient secretion across the epithelium, therefore, could be detrimental as it would impede on 
proper development. Numerous transporter families expressed in the mammary gland during 
lactation are responsible for the transport of both nutrients and non-nutrient elements including 
various drugs setting up the high potential for interactions to occur (61). Despite this, drug-
nutrient transporter interactions at the mammary epithelium and the consequences of said 
interactions have received very limited attention. 
Recent studies in our laboratory have shown an important drug-nutrient transport 
interaction at the mammary gland involving L-carnitine, a conditionally essential nutrient 
required by the neonate for proper development. Several transporters mediate the transport of L-
carnitine, namely the OCTN transporters, however, substrates of these transporters also include 
cationic drugs such as verapamil, valproate, and the β-lactam antibiotics, cephaloridine and 
cefepime (62). When administered, cefepime significantly reduced the milk concentration of L-
carnitine in early lactation (day 4), theoretically, through an interaction with OCTN2 (9).  
Further analysis of interactions at the mammary epithelium is absolutely critical due to the 
potential for serious adverse effects to occur. The developing neonate is in a sensitive state, 
therefore, any maternal factor (e.g. disease, diet, exposure to xenobiotics) that adversely alters 
breast milk composition could reflect negatively on the proper development on the infant (63). 
Yet, drug-nutrient transporter interactions at the lactating mammary epithelium represent a 
fundamental knowledge gap that desperately needs to be filled. 
 
2.6.2 Interactions at the Intestinal Epithelium 
Drug-nutrient interactions have been extensively studied and well documented in the GI 
tract. Primarily, intestinal transporters are responsible for the absorption of molecules that are 
produced during digestion of food; however, they additionally are an important site of secretion 
of many substrates via efflux transporters (59). With the high degree of absorbance and 
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secretion, there is a high chance of an interaction occurring between essential nutrients and other 
substrates including drugs. Disruptions of nutrient availability in the GI tract through these 
interactions have the potential to lead to adverse effects including pathogenesis. This is 
exemplified in the case of IBD where there is an impairment of butyrate metabolism and L-
carnitine availability and a switch to glucose utilization due, in part, to downregulation and/or 
loss of function of the butyrate transporter, MCT1, and high affinity L-carnitine transporter, 
OCTN2 (64).   
Numerous substrates have been shown to inhibit the transporter MCT-1 in the GI tract. A 
key interaction that has been documented involves the compound α-cyano-4-hydroxycinnamate 
(4-CIN), which has the potential to competitively inhibit MCT-1 in human colonic cancer cells 
(65). This is of particular concern as MCT1 is the primary transporter involved in the transporter 
of butyrate, the main energy source for colonic cells. Further, this compound inhibits the entry of 
pyruvate into mitochondria and prevents the subsequent metabolism of pyruvate derived from 
glucose potentially having effects on energy metabolism through the tricarboxylic acid cycle 
(TCA cycle) (66). Any disruption in the availability of butyrate is of concern due to the impacts 
on cell homeostasis. 
 
2.7 Two Transported Nutrients Important in Epithelial Energy Metabolism: L-
Carnitine and Butyrate 
 
2.7.1 L-Carnitine 
L-Carnitine is a water soluble molecule that is conditionally essential in neonates as L-
carnitine biosynthesis is developmentally immature and neonates, therefore, rely solely on 
maternal sources through breast milk to meet their needs (9, 67). This nutrient is critical for the 
proper development of the cardiovascular and neurological systems in all nursing neonates (68). 
L-Carnitine is essential for the utilization of long chain fatty acids (LCFAs) as it facilitates the 
transport into the mitochondrial matrix (69). Oxidation of LCFAs is necessary for the normal 
development and survival of the developing neonate (69). All enzymes required for β-oxidation 
of LCFAs are located within the matrix and, therefore, there must be adequate concentrations of 
L-carnitine in the tissues or β-oxidation will decrease and cellular energy metabolism impaired 
(69). L-Carnitine serves other physiological roles in the body including activation of aerobic 
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glycolysis, enhancement of respiratory chain function, donor of acetyl groups for biosynthesis 
(e.g. acetyl choline) and membrane stabilization (68). 
With the many functions of L-carnitine, a deficiency can result in severe and even lethal 
consequences. Since L-carnitine is critical for the production of energy for many organs, 
deficiencies have been associated with cardiomyopathy, muscle weakness, encephalopathy 
and/or hepatopathy including Reyes syndrome (70). Further, deficiencies in L-carnitine have 
been related to limb girdle myopathy, failure to thrive and recurrent hypoketotic, hypoglycemic 
coma and seizures which have the potential to be lethal (71). However, the majority of symptoms 
are reversible with high-dose life-long oral L-carnitine supplementation (71). 
Several transporters mediate the transport of L-carnitine including organic cation/carnitine 
transporters (OCTN1, OCTN2 and OCTN3) (9). Total concentration of L-carnitine in human 
tissues is highest in the heart and skeletal muscle, as opposed to the liver and brain, which 
reflects the higher rate of LCFA oxidation that occurs in these tissues (72). Initial concentrations 
of L-carnitine in the neonate directly depend on the maternal concentrations as neonates lack the 
ability to synthesize their own L-carnitine (73). Plasma concentrations of this conditionally 
essential nutrient increases during the first two weeks of life and reach adult levels by six months 
following parturition (74). 
 
2.7.2 Butyrate 
Butyrate, a short chain fatty acid (SCFA), plays an important role in maintaining the 
health and integrity of the colonic mucosa (55). Butyrate, acetate, and propionate, the 
predominant SCFAs, are absorbed readily by colonocytes and are used as the preferred source of 
fuel by these cells (75). Butyrate is oxidized more readily than propionate and acetate by 
colonocytes and its oxidation occurs regardless of the presence of other SCFAs (76). Due to this, 
β-oxidation of butyrate accounts for up to 70% of the totally energy consumed by the 
colonocytes (77). Further, butyrate promotes proliferation and differentiation of colonic 
epithelial cells, modulates the proliferative potential of cultured human colon tumour cell lines 
(78) as well as involved in the activation of several differentiation-specific genes (79, 80). At 
colonic pH, SCFAs exist almost entirely as anions and require a carrier protein for cellular entry 
(81). Transport of butyrate across the apical membrane involves the monocarboxylate transporter 
family, specifically, MCT1 (54, 82). Therefore, any modulation to the expression of MCT1 
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would reduce the intracellular availability of butyrate, disrupting not only cell energy 
metabolism but cell regulatory effects (55). 
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2.8 Hypothesis and Objectives 
Transport of essential nutrients across the mammary and intestinal epithelium is achieved 
by nutrient transporters. However, these transporters’ substrate profile includes numerous 
xenobiotics as well as the nutrients setting up the potential for drug-nutrient transporter 
interactions to occur. Any disruption to the availability of nutrients by the maternal mammary 
gland or the absorbance of the nutrients at the neonatal intestinal gland may adversely impact the 
health and development of the breastfeeding neonate, in particular, through altered cellular 
homeostasis. Therefore, we evaluated the inhibition of nutrient-transporter mediated uptake of 
important nutrients required for the maintenance of cellular homeostasis. This will be used as a 
proof of concept to represent the plausible effects that can occur to the mother-neonate dyad 
when the mother requires medication while nursing her infant. 
 
2.8.1 Hypothesis 
Inhibition of L-carnitine or butyrate transport disrupts epithelial barrier integrity through a 
reduction in cellular energy metabolism and loss of tight junction function. 
 
2.8.1.1 Objective I 
Assess the acute and chronic effects of L-carnitine and butyrate transport inhibition on the 
integrity of the intestinal and mammary epithelium by measuring transepithelial electrical 
resistance (TEER), Lucifer Yellow rejection rates, and transporter expression. 
 
2.8.1.2 Objective II 
Assess the acute and chronic effects of L-carnitine and butyrate transport inhibition in mammary 
epithelial and GI epithelial barriers on cellular energy metabolism by measuring cellular 
respiration, glycolysis rate, and cellular ATP. 
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3. MATERIALS AND METHODS 
 
3.1 Chemicals, Reagents, Kits, and Cell Culture Materials 
Caco-2 intestinal cell line was purchased from American Tissue Culture Collection 
(Rockville, MD) and the Bovine Mammary Epithelium cell line was a generous gift from Dr. 
Bruce Schultz from Kansas State University, Manhatten, KS, USA. T-75 flasks, sterile 15 mL 
and 50 mL polypropylene centrifuge tubes, 96 well plates, eppendorf tubes, NCTC-135 cell 
culture media, Fetal Bovine Serum (FBS), Newborn Calf Serum (NCS), Iron Supplemented 
Bovine Calf Serum (FeBCS), Insulin-transferrin-sodium selenite, and SuperScript VILO cDNA 
Synthesis Kit were purchased from Thermo Fisher Scientific (Ottawa, Ontario, Canada. 
Dulbecco's Modified Eagle's Medium (DMEM), Ham’s F-12 medium (DMEM-F12), and RPMI-
1640 cell culture medium as well as dimethyl sulfoxide (DMSO) was purchased from American 
Type Culture Collection (ATCC) (Rockville, Maryland, USA). Corning® HTS Transwell-24 
well permeable supports, Calcein-AM kit, and Lucifer Yellow were purchased from Sigma-
Aldrich (Oakville, Ontario). Verapamil was purchased from Cayman Chemical Company, CAS 
No. 152-11-4 (Michigan, USA). AR-C155858 was purchased from Tocris Bioscience, CAS No. 
4960 (Bristol, UK).  Ribonucleic acid (RNA) isolation midi kit was purchased from Qiagen Inc. 
(Toronto, Ontario, Canada).  Quantitative reverse transcription-polymerase chain reaction 
(qPCR) tubes and one-step SYBR green RT-PCR kits were acquired from Applied Biosystems 
(Foster City, California, USA). CellTiter-Glo Luminescent Cell Viability Assay was purchased 
from Promega (Madison Wisconsin, USA). MitoXpress Xtra Oxygen Consumption Assay and 
pH-Xtra Glycolysis Assay was purchased from Luxcel Biosciencs (Cork, Ireland). Highly 
purified deionized water was obtained from a MilliQ Synthesis water purification system 
(Millipore, Bedford, MA). All other solvents and reagents used were of the highest analytical 
grade available. 
 
3.2 Cell Lines 
For all experiments, we made use of the Caco-2 (human colorectal adenocarcinoma) and 
BME-UV (bovine mammary) polarized epithelial cell lines as both of these in vitro models have 
functional and morphological characteristics that mimic the in vivo system. Although the Caco-2 
cell line is not neonatal in origin, it served as a substitute for this proof of concept study. Caco-2 
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polarized epithelial cells have routinely been cultivated into monolayers to study transepithelial 
transport of drugs across the intestinal epithelium (83). BME-UV polarized epithelial cell line is 
a newer model that has been shown to form a confluent, polarized monolayer capable of 
regulated ion transport allowing the characterization of the mammary epithelium (84). Further, 
both Caco-2 and BME-UV cells lines express the transporters involved in the high affinity 
transport of L-carnitine and butyrate into epithelial cells, namely OCTN2 and MCT1, 
respectively (85, 86). 
 
3.2.1 Caco-2 
Caco-2 cells were cultured under conditions similar to those described previously (83). The 
cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic 
solution (10,000 units penicillin, 10 mg/mL streptomycin) in T-75 flasks. The media was 
changed every second day. Cells were passaged at 70% confluency twice after removal from 
liquid nitrogen. Passage of cells in the flasks were performed by aspirating spent medium from 
the flask, rinsing with Trypsin (0.25% in phosphate-buffered saline; PBS) containing 0.2% 
EDTA to neutralize the FBS, and then incubated with 5 mL of Trypsin for 5 minutes to allow the 
cells to detach. Ten mL of media (DMEM with 10% FBS and 1% antibiotics) was added to stop 
the Trypsin and the total suspension was added to a 15 mL centrifuge tube and centrifuged for 5 
mins at 1000 rpm. Media was aspirated and the cell pellet was re-suspended in 10 mL of fresh 
media.  
  
3.2.2 BME-UV 
BME-UV cells were cultured under conditions similar to those described previously (87). 
Cells were cultured in Typical Bovine Media (Table 3.1) in T-75 flasks. Before use, all media 
was supplemented with 1% insulin-transferrin-sodium selenite and 1% penicillin-streptomycin 
and pH adjusted to 7.4. Passaging was performed the same as with Caco-2 cells. 
 
Table 3.1: Typical Bovine Media Composition 
Component  Amount 
Dulbecco's Modified Eagle Media (DMEM) 21.25% 
Ham F-12 nutrient mixture (F-12) 21.25% 
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RPMI-1640 25.50% 
NCTC-135 17% 
Fetal Bovine Serum (FBS) 10% 
Newborn Calf Serum (NCS) 3% 
Iron-supplemented Bovine Calf Serum (FeBCS) 2% 
Lactalbumin Hydrosylate 1 mg/mL 
L-Ascorbic  10 μg/mL 
Lactose 2 mM 
*Before use, all media was supplemented with 1% insulin-transferrin-sodium selenite and 1% 
penicillin-streptomycin. Media was made in 500 mL increments and pH adjusted to 7.3, filter-
sterilized with 0.22 µm filters and stored in opaque bottles at 4°C. 
 
3.3 Optimization Studies to Identify Inhibitor Concentration 
Optimization studies were performed to determine nontoxic concentration ranges of the 
proposed transport inhibitors for subsequent studies and made use of the Calcein-AM kit. Cells 
were seeded onto 96-well plates at a density of 10,000 cells/288 µL per well. The cells were 
allowed 24 hours to attach, and then were exposed to a serial dilution range of the transporter 
inhibitors (Verapamil concentration range from 10 nM-10 mM and AR-C155858 concentration 
range from 6.5 pM-6.5 µM made in 1% DMSO diluted in media). The solvents were made by 
plating 100% DMSO at 100x the concentration as needed. 22 µL of the 100% DMSO samples 
were added to 198 µL of media to create a 10% DMSO solvent. 32 µL of the 10% DMSO 
solvent was added to the seeded plate containing 288 µL of media creating 1% DMSO 
concentration. Wells were also treated with the vehicle mixture of 1% DMSO to ensure no 
cytotoxicity occurred and to give background readings as well as 5-Flurouracil (also dissolved in 
1% DMSO) as a positive control. Cells were treated and allowed to incubate for 72 hours at 
37°C and 5% CO2. Following incubation, spent media was aspirated and cells were washed with 
Calcein washing buffer, followed by the addition of 100 µL of Calcein working solution (10 µL 
of 2 mM Calcein added to 10 mL PBS) and incubated for 30 minutes at 37°C and 5% CO2. 
Following incubation, the fluorescence was read at 485/530 nm. IC50 values were calculated on 
GraphPad Prism 5 (San Diego, California, USA) with nonlinear regression.  
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3.4 Assessing Barrier Integrity 
On three separate occasions, cells were seeded at a density of 1x10
5
 cells/well on polyester 
membrane transwells (Figure 3.1) in the apical compartment (inserts measure 24 mm in diameter 
and have a pore size of 0.4 µm). Both cell lines were washed and new media was added every 
two days for three weeks. Initial TEER measurements were obtained using a Millicell-ERS volt-
ohmmeter by placing one electrode in the apical compartment (basket) and the other in the 
basolateral compartment (well). A TEER measurement of >300Ω is used as a baseline to 
represent a polarized monolayer.  Cells were exposed to IC50 values of the inhibitors (either 
Verapamil or AR-C155858) in replicates of three for acute durations of 6, 12 and 24 hours and 
for a chronic duration of 7 days. Treatment was done in the apical compartment for Caco-2 cells 
as exposure is in the lumen and in the basolateral compartment for BME-UV cells as exposure is 
in the systemic circulation. TEER values and Lucifer Yellow (LY) rejection rates were measured 
at each time point on three separate occasions. 
      
Figure 3.1: A schematic representation of the Transwell-based approach for in vitro barrier 
integrity assessment. A transwell insert with a microporous membrane (representing the apical 
compartment) rests in a well (representing the basolateral compartment). Cells are seeded in the 
apical compartment and the porous membrane allows the cells to interact with media on either 
side. Cells are cultured for a determined amount of time allowing a polarized monolayer to form.  
 
3.4.1 Lucifer Yellow Rejection Rates 
LY is routinely used to assess barrier integrity as it solely transverses the membrane by the 
paracellular route. Therefore, it is used as a measurement of barrier ‘tightness’. An intact 
polarized barrier will reject ~99% of the LY. To make the LY solution, one mg of LY was 
dissolved in Hank`s Balanced Salt Solution (HBSS) with 2% HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) added and stored at 4°C in an opaque tube. Media was carefully 
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removed in the apical compartment (basket of transwell) using suction as to not disrupt the 
monolayer of cells and washed twice with HBSS and HEPES solution and then 200 µL of 
Lucifer Yellow suspension was added. Media was removed from the basolateral compartment 
and replaced with HBSS and HEPES solution. The plate was incubated for 2 hours in 37°C at 
5% CO2. The transwell inserts were removed and the fluorescence of the basolateral 
compartment was read at 485/535 nm. 
 
3.5 Acute and Chronic Effects of Inhibitor Exposure on Expression of Transporters 
 
3.5.1 Total RNA Extraction 
Following acute and chronic exposure to the inhibitors and measurement of LY rejection 
rates, cells were washed twice with HBSS with HEPES to remove any remaining LY. Two 
hundred µL of Trizol was added and was left to sit for 1 min to allow cell lysis and then the 
sample was collected and stored at -80°C. Total RNA was extracted using RNeasy Midi Kits 
according to manufacturer’s instructions. Frozen cell pellets were thawed for 20 minutes at room 
temperature on counter sprayed with RNAseZAP. Cell lysate was then homogenized with 350 
μL of buffer RLT containing β-ME and added to 1 volume of 70% ethanol to precipitate the 
nucleic acids. The cell lysate was then applied to the Midi column and a series of buffers were 
added to remove the cellular contaminants according to the manufacturer’s instructions. The 
purified RNA was isolated from the column using RNase-free water (30 μL). The concentration 
and purity of isolated total RNA was determined using a Nanoview UV spectrophotomer (GE 
Healthcare Life Sciences, Quebec, Canada). Total RNA was quantified by measuring the 
absorbance of a diluted RNA (RNA:RNase-free water) at 260 nm according to the following 
formula:  
Concentration of RNA = 40 μg/mL × A260 × Dilution factor 
RNA purity was assessed by measuring absorbance ratio (A260 / A280) of a diluted sample of 
RNA (RNA:10 mM TrisCl (pH-7.5)). Pure RNA has a ratio between 1.9-2.1. Al1 samples used 
for qPCR were of high purity. Total RNA was stored at -80°C until analysis.  
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3.5.2 Primer Design 
Gene sequences for OCTN1, OCTN2, MCT1, MCT2, and GADPH were obtained from the 
National Center for Biotechnology Information Gene Bank (NCBI) and specific primers were 
designed using Integrated DNA Technologies 
(https://www.idtdna.com/Primerquest/Home/Index).  
Table 3.2: Primer sequences and annealing temperatures of selected transporters of 
interested designed using Integrated DNA Technologies. 
Target Gene Primer Sequence (5'-3') 
Annealing 
Temperature (°C) 
 
hOCTN1 
F: GACAGGTTTGGCAGGAAGAA 
R: CATGCCCACGATGACAAATAAC 
55.2 
54.5 
hOCTN2 
F: GGGAGGTAGCATTTCCAATAA 
R: CATCAGAGGCTCCCAAATCTAC 
54.6 
55.0 
hMCT1 
F: GCTAGCACCTTTATCCACTACC 
R: GGTCCAACAAGGTCCATCAA 
55.0 
55.0 
hMCT2 
F: ATGGTGTTGGCCTCCTTTAG 
R: CAATTATGGTTAAGGCGGGTTG 
54.9 
54.4 
hGADPH 
F: GGTGTGAACCATGAGAAGTATGA 
R: GAGTCCTTCCACGATACCAAA 
54.5 
55.1 
bOCTN1 
F: CCCTGAAGCAGCAGAAAGT 
R: CCACTGAGGTCAACATCCATAG 
55.2 
54.9 
 
bOCTN2 
F: TCTTGGCAAGTCAGTTCGTATTA 
R: CGCCAGTCTCTGATGAAGTAAG 
54.0 
55.0 
bMCT1 
F: TGTGGGACTGAAGGGTAAATG 
R: CCTGGTATGATTCCCACAGAAA 
54.6 
54.5 
 
bMCT2 
F: AGAAACGACCTGTAGCGAATG 
R: GCTTCCCTTCCAACCATAAGT 
54.9 
54.9 
bGAPDH 
F: TGAGATCAAGAAGGTGAA 
R: GCATCGAAGGTAGAAGAGTGA 
54.4 
54.8 
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3.5.3 Optimization of Primers  
 Primer optimization was done using a SYBR Green RT-PCR reagent kit and an Applied 
Biosystems Real-Time PCR System (Foster City, California, USA). Primers were reconstituted 
to 100 µmol/L and then diluted to 5 µmol/L using UltraPure Distilled Water. Seven µL of SYBR 
Green, 2 µL of the respective forward and reverse primer, and 2 µL of 2 ng RNA (human or 
bovine) was added in a 96 well plate and spun down. Initial activation step (1 cycle at 95°C for 
15 min) was followed by a three step thermal cycling (40 cycles; denaturing at 95°C for 15s, 
annealing at 60°C for 30s, and extension at 60°C for 30s). Finally, a melt curve analysis from 
65°C to 95°C at 0.5°C/s was performed. Only primers that bound to one product and had a CT 
value less than 25 were chosen and used for analysis. 
 
3.5.4 cDNA Synthesis 
 cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit and a MyCycler 
Thermal Cycler System (Foster City, California, USA). Due to low RNA extraction yields 
(average of 50 ng/µL), 14 µL of RNA was added to 4 µL of VILO Reaction Mix and 2 µL of 
SuperScript Enzyme Mix. This kit allows for a dilution of 20x when RNA amounts exceeded 
100 ng and this step was neglected due to low RNA yields. Contents were mixed and then 
incubated at 25°C for 10 minutes and then incubated at 42°C for 60 minutes. The reaction was 
terminated at 85°C for 5 minutes and the cDNA was stored at -20°C. 
 
3.5.5 Quantitative Reverse Transcription-Polymerase Chain Reaction 
(qPCR) 
The relative expression of mammary and intestinal monocarboxylate and L-carnitine 
transporters was determined using qPCR. One step qPCR reactions were performed using a 
SYBR Green RT-PCR reagent kit and an Applied Biosystems Real-Time PCR System (Foster 
City, California, USA). A 20 µL reaction mixture of 2x concentrated Power SYBR Green master 
mix, an optimized concentration of cDNA, gene specific qPCR primers, and nuclease free water 
was prepared for each cDNA sample and primer combination. Reactions were conducted in 
triplicate with an optimized 13 µL reaction volume per well. The reactions were quantified 
following determination of the threshold cycle (CT; the amplification cycle when PCR products 
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are first detected above baseline fluorescence) and fluorescence was measured from the 
intercalation of SYBR green dye into the double stranded product after the primer elongation 
phase. A non-template negative control was incorporated into all analysis runs. PCR products 
were analyzed using comparative CT or 2
-ΔΔC
T method. Initial activation step (1 cycle at 95°C for 
15 min) was followed by a three step thermal cycling (40 cycles; denaturing at 95°C for 15s, 
annealing at 60°C for 30s, and extension at 60°C for 30s). Finally, a melt curve analysis from 
65°C to 95°C at 0.5°C/s was performed.  
 
3.6 CellTiter-Glo® Luminescent Cell Viability 
Cells were seeded at a density of 50,000 cells/100 µL per well in luminescent 96 well 
plates and incubated at 37°C with 5% CO2 for 24 hours to allow for cell attachment. Control 
wells were also prepared containing media without cells to obtain a value for background 
luminescence. Following the 24 hour incubation the cells were treated with either Verapamil or 
AR-C155858 at their respectable IC50 concentrations for 6 hours. After treatment, the cells were 
allowed to equilibrate to room temperature for 30 minutes. During this time, the CellTiter-Glo 
Buffer and Substrate were thawed and allowed to equilibrate to room temperature prior to use. 
Ten mL of Buffer was added to Substrate to reconstitute the lyophilized enzyme/substrate 
mixture forming the CellTiter-Glo Reagent. The Reagent was mixed by gently inverting. 
Reagent was added to the wells within 1 minute of preparation. A 100 µL volume of Reagent 
was added to each well and the contents were mixed for 2 minutes on an orbital shaker to induce 
cell lysis. The plate was allowed to incubate at room temperature to stabilize the signal and then 
the luminescence was recorded. Assay was performed in triplicate on three separate occasions. 
 
3.7 pH-Xtra Glycolysis Assay 
Cells were seeded at a density of 50,000 cells/100 µL per well in 96 well plates and 
incubated at 37°C with 5% CO2 for 24 hours to allow them to attach. Control wells were also 
prepared containing media without cells to obtain a value for background signal. Respiration 
Buffer tablet was reconstituted in 50 mL of water and the pH was adjusted to 7.4 and filter 
sterilized using a 0.22 µm filter. One mL of Respiration Buffer was added to the pH-Xtra vial 
and the contents were reconstituted by gently inverting. Prior to commencing the assay, all media 
and stock solutions used were pre-warmed to 37°C prior to use and the plate was kept on a block 
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heater during plate preparation. Spent medium was removed for the wells and washed twice 
using 100 µL of Respiration Buffer. After the second wash, 150 µL of fresh Respiration Buffer 
was added. Ten µL of the reconstituted pH-Xtra reagent was added to each well, except those 
used as blank controls. Ten µL of either inhibitor was added at the concentration of their 
respective IC50 value. Ten µL of 10 µM of Antimycin (Complex III Inhibitor) was used as a 
negative control. The plate was read kinetically for 120 minutes on a fluorescence plate reader at 
320/620nm. Assay was performed in triplicate on three separate occasions. 
 
3.8 MitoXpress Xtra Oxygen Consumption Assay 
Cells were seeded at a density of 50,000 cells/100 µL per well in 96 well plates and 
incubated at 37°C with 5% CO2 for 24 hours to allow them to attach. Control wells were also 
prepared containing media without cells to obtain a value for background signal. The contents of 
the MitoXpress Xtra vial was reconstituted in 1 mL of DMEM and gently inverted to mix. Prior 
to commencing the assay, all media and stock solutions used were pre-warmed to 37°C prior to 
use and the plate was kept on a block heater during plate preparation. Following the 24 hour 
incubation, spent culture media was removed and replaced with 150 µL of fresh media. Ten µL 
of the reconstituted MitoXpress reagent was added to each well, except those used as blank 
controls. Ten µL of either inhibitor was added at the concentration of their respective IC50 value. 
Ten µL of 10 µM of Antimycin (Complex III Inhibitor) was used as a negative control. The plate 
was read kinetically for 120 minutes on a fluorescence plate reader at 380/645nm. Assay was 
performed in triplicate on three separate occasions. 
 
3.9 Statistical Analysis 
Data was analyzed by one-way or two-way ANOVA followed by Tukey’s multiple 
comparison test as appropriate. A P-value > 0.05 was taken to indicate a significant difference 
between the means of sets of data. All experiments were conducted in triplicate on three separate 
occasions with the data being expressed as mean ± standard deviation (SD).  
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4. RESULTS 
4.1 Barrier Integrity – TEER measurements and LY Rejection Rates 
To assess the integrity of the epithelial systems, cells were seeded in polyester membrane 
transwells in the apical compartment (inserts measure 24 mm in diameter and have a pore size of 
0.4 µm) and allowed 3 weeks to form a polarized epithelium. Initial TEER measurements were 
obtained using a Millicell-ERS volt-ohmmeter and a TEER measurement of >300Ω is used as a 
baseline to represent a polarized monolayer.  Cells were exposed to IC50 values of the inhibitors 
(either Verapamil or AR-C155858) in replicates of three for acute durations of 6, 12 and 24 
hours and for a chronic duration of 7 days with TEER values and Lucifer Yellow (LY) rejection 
rates measured at each time point on three separate occasions. No significant variation for TEER 
values and LY rejection rates were found at any time point between the control and treated 
groups in either cell line. 
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Figure 4.2: Mean ± SD of transepithelial electrical resistance (TEER) values in Caco2 cells at 5 
different time points with and without treatment of butyrate or L-carnitine transporter inhibitors 
ran in replicates of three on three separate occasions. A TEER measurement of 300Ω is used as a 
threshold to represent a polarized monolayer has formed. Initial TEER values were taken prior to 
treatment and were taken again at 6, 12, 24 hr and 7 days post-treatment (PT). Means were 
compared using one-way ANOVA (P < 0.05) followed by Tukey’s test to know the interaction 
between control and treatment groups. No significant difference was determined between control 
and treatment groups. 
 
 
Figure 4.3: Mean ± SD of transepithelial electrical resistance (TEER) values of BME-UV cells 
at five different time points with and without treatment of butyrate or L-carnitine transporter 
inhibitors ran in replicates of three on three separate occasions. A TEER measurement of 300Ω 
is used as a threshold to represent a polarized monolayer has formed. Initial TEER values were 
taken prior to treatment and were taken again at 6, 12, 24 hr and 7 days post-treatment (PT). 
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Means were compared using one-way ANOVA (P < 0.05) followed by Tukey’s test to know the 
interaction between control and treatment groups. No significant difference was determined 
between controls and treatment groups. 
  
 
Figure 4.4: Mean ± SD of Lucifer Yellow (LY) Rejection Rate percentages of Caco-2 cells at 4 
different time points with and without treatment of butyrate or L-carnitine transporter inhibitors 
ran in replicates of three on three separate occasions. A rejection rate of >95% is used as a 
threshold to represent an intact barrier has formed. LY rejection rates were measured following 
treatment for 6, 12, 24 hr and 7 days. Means were compared using one-way ANOVA (P < 0.05) 
followed by Tukey’s test to know the interaction between control and treatment groups. No 
significant variation was determined between control and treatment groups. 
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Figure 4.5: Mean ± SD of Lucifer Yellow (LY) Rejection Rate percentages of BME-UV cells at 
4 different time points with and without treatment of butyrate or L-carnitine transporter 
inhibitors ran in replicates of three on three separate occasions. A rejection rate of >95% is used 
as a threshold to represent an intact barrier has formed. LY rejection rates were measured 
following treatment for 6, 12, 24 hr and 7 days. Means were compared using one-way ANOVA 
(P < 0.05) followed by Tukey’s test to know the interaction between control and treatment 
groups. No significant variation was determined between controls and treatment groups. 
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4.2 Barrier Integrity – Transporter Expression 
To assess the expression of key transporters involved in the transport of L-carnitine and 
butyrate following acute (6, 12, and 24 hours) and chronic (7 days) exposure to their respective 
drug inhibitors, RNA was extracted for qPCR analysis. A low RNA yield was noted and cDNA 
synthesis protocol was altered to compensate. qPCR reactions were ran with poor results. Only 
the housekeeping gene (GADPH) was observed in Caco-2 cells along with OCTN1 and OCTN2 
in BME-UV cells, however, CT values were too high to be quantified appropriately by the 
instrument. 
 
Figure 4.6: Real time RT-PCR readout of the association stage looking at an increase in 
fluorescence (from the intercalation of SYBR Green dye in amplifying DNA) with PCR cycle in 
Caco-2 cells.  The transporters OCTN1, OCTN2, MCT1, MCT2 and the housekeeping gene, 
GADPH, were measured with each line representing the amplification of an individual 
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transporter. Only GADPH was amplified, but all CT values were too high to be detected by the 
instrument, therefore, the expression could not be quantified. 
 
Figure 4.7: Real time RT-PCR readout of the association stage looking at an increase in 
fluorescence (from the intercalation of SYBR Green dye in amplifying DNA) with PCR cycle in 
BME-UV cells.  The transporters OCTN1, OCTN2, MCT1, MCT2 and the housekeeping gene, 
GADPH, were measured with each line representing the amplification of an individual 
transporter. Only OCTN1, OCTN2 and GADPH were amplified, but all CT values were too high 
to be detected by the instrument, therefore, the expression could not be quantified. 
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4.3 Cellular Homeostasis – ATP Synthesis 
To assess ATP Synthesis, the CellTiter-Glo Luminescent Cell Viability Assay was used 
which is a method used to determine the number of viable cells based on the quantification of 
ATP present. A direct relationship exists between luminescence measured and the number of 
cells in culture which is directly proportional to the amount of ATP. No significant variation was 
found between the control groups and the treated groups in either cell lines. 
 
 
Figure 4.8: Values represent the mean ± SD of the ATP Synthesis by Caco-2 cells with and 
without treatment of butyrate or L-carnitine transporter inhibitors within 3 replicates on 3 
separate occasions. A direct relationship exists between luminescence measured and number of 
cells in the culture which is directly proportional to ATP synthesis. Means were compared using 
one-way ANOVA (P < 0.05) followed by Tukey’s test to know the interaction between control 
and treatment groups. No significant difference was determined between controls and treatment 
groups. 
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Figure 4.9: Values represent the mean ± SD of the ATP Synthesis by BME-UV cells with and 
without treatment of butyrate or L-carnitine transporter inhibitors within 3 replicates on 3 
separate occasions. A direct relationship exists between luminescence measured and number of 
cells in the culture which is directly proportional to ATP synthesis. Means were compared using 
one-way ANOVA (P < 0.05) followed by Tukey’s test to know the interaction between control 
and treatment groups. No significant variation was determined between controls and treatment 
groups. 
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4.4 Cellular Homeostasis – Glycolysis 
 To assess glycolytic flux, the pH-Xtra Glycolysis Assay was used which measures the 
real-time, kinetic analysis of extracellular acidification (ECA) rates. Lactate production is the 
main contributor to ECA; therefore, the measurement of ECA is a convenient measurement of 
cellular glycolytic flux. Cells were seeded at a density of 50,000 cells/well (for both cell lines) 
and allowed to attach before being treated for 6 hours with the respective inhibitor.  Optional 
controls were noted in the protocol, and three out of the four were employed. Blank controls 
were free from the addition of pH-Xtra Reagent and signal controls included wells left absent 
from the addition of cells. Antimycin A was used as a positive control as it blocks cellular 
respiration resulting in an increase in lactate formation. Upward trends were noted in both the 
Caco-2 cells and the BME-UV cells as well as wells treated with both inhibitors over the 120 
minute period. 
 
Figure 4.10: Representative graph of pH-Xtra Glycolysis Assay of Caco-2 cells treated with AR-
C155858. This is a plot of relative fluorescence units (RFU) as a function of time where 
increases in RFU indicate increasing extracellular acidification (ECA). The slope of the graph is 
equivalent to the ECA measurement. An upward trend was noted in all wells treated with the 
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IC50 of AR-C155858 (butyrate inhibitor) and Verapamil (L-carnitine inhibitor) in both the Caco-
2 cell line as well as the BME-UV cell line.  
 
 
Figure 4.11: Representative graph of pH-Xtra Glycolysis Assay of Caco-2 cells treated with the 
positive control, Antimycin A. Antimycin A blocks cellular respiration resulting in an increase in 
lactate formation, which further results in an increase in extracellular acidification (ECA). This is 
a plot of relative fluorescence units (RFU) as a function of time where increases in RFU indicate 
increasing ECA. The slope of the graph is equivalent to the ECA measurement. An upward trend 
was noted in all wells treated with Antimycin A. 
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Figure 4.12: Representative graph of pH-Xtra Glycolysis Assay of wells of Caco-2 cells 
untreated with transporter inhibitor. This is a plot of relative fluorescence units (RFU) as a 
function of time where increases in RFU indicate increasing extracellular acidification (ECA). 
The slope of the graph is equivalent to the ECA measurement. 
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Figure 4.13: Representative graph of pH-Xtra Glycolysis Assay of the Blank Control (no pH 
Xtra added) in Caco-2 cells. This is a plot of relative fluorescence units (RFU) as a function of 
time where increases in RFU indicate increasing extracellular acidification (ECA). The slope of 
the graph is equivalent to the ECA measurement. 
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4.5 Cellular Homeostasis – Oxygen Consumption 
 To assess oxygen consumption rates the MitoXpress Xtra Oxygen Consumption Assay 
was used which measures the real-time, kinetic analysis of cellular respiration. The slope of the 
graph is representative of the Oxygen Consumption Rate (OCR). Cells were seeded at a density 
of 50,000 cells/well (for both cell lines) and allowed to attach before being treated for 6 hours 
with the respective inhibitor.  Optional controls were noted in the protocol, and three out of the 
four were employed. Blank controls were free from the addition of MitoXpress Reagent and 
signal controls included wells left absent from the addition of cells. Antimycin A was used as a 
negative control as it is a Complex III inhibitor. 
 
 
Figure 4.14: Representative graph of MitoXpress Xtra Oxygen Consumption Assay of Caco-2 
cells treated with Verapamil. This is a plot of relative fluorescence units (RFU) as a function of 
time where increases in RFU indicate increasing oxygen consumption rate (OCR). The slope of 
the graph is equivalent to the OCR. An upward trend was noted in all wells treated with the IC50 
of AR-C155858 (butyrate inhibitor) and Verapamil (L-carnitine inhibitor) in both the Caco-2 cell 
line as well as the BME-UV cell line. 
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Figure 4.15: Representative graph of MitoXpress Xtra Oxygen Consumption Assay of Caco-2 
cells treated with the negative control, Antimycin A. This is a plot of relative fluorescence units 
(RFU) as a function of time where increases in RFU indicate increasing oxygen consumption 
rate (OCR). The slope of the graph is equivalent to the OCR.  
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Figure 4.16: Representative graph of MitoXpress Oxygen Consumption Assay of wells of Caco-
2 cells untreated with transporter inhibitor. This is a plot of relative fluorescence units (RFU) as 
a function of time where increases in RFU indicate increasing oxygen consumption rate (OCR). 
The slope of the graph is equivalent to the OCR.  
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Figure 4.17: Representative graph of MitoXpress Oxygen Consumption Assay of the Blank 
Control (no MitoXpress added) in Caco-2 cells. This is a plot of relative fluorescence units 
(RFU) as a function of time where increases in RFU indicate increasing oxygen consumption 
rate (OCR). The slope of the graph is equivalent to the OCR.  
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5. DISCUSSION 
 
The transporters primarily responsible for transporting the essential nutrients (L-carnitine 
and butyrate) involved in energy metabolism, OCTN2 and MCT1, have a wide substrate 
specificity setting up the potential for drug-nutrient transporter interactions. Pharmacological 
inhibition of nutrient transport across the lactating mammary and neonatal intestinal epithelial 
barrier can directly and indirectly affect growth and maturation of the developing neonate. This 
can be the result of direct competitive inhibition of these key nutrient transporters. Such 
inhibition might cause a reduction in the flux of L-carnitine and butyrate across the barriers 
decreasing their availability to the developing neonate. Due to the essentiality of these nutrients 
on energy metabolism, pharmacological inhibition of these transporters may also have indirect 
effects through an ability to disrupt barrier integrity due to a loss of cellular homeostasis. In 
particular, loss of intestinal barrier integrity may have important adverse effects on the neonate 
including sepsis and malnutrition.  
Drug-nutrient interactions have been well documented in many systems including the GI 
tract, kidney and liver while some areas, including the mammary gland, have received limited 
attention (59). Drug induced inhibition of nutrient transporters, such as MCT1 and OCTN2, is 
increasingly being recognized as an important toxicological mechanism due to the possibility for 
severe consequences related to such interactions (9, 57). Although limited research is available, a 
few studies in the literature indicate the possibility of pharmacological inhibition of nutrient 
transporters at the mammary epithelium. Previous work in the Alcorn lab has shown 
pharmacological inhibition of transporters at the mammary gland impacts milk concentrations of 
L-carnitine, thus affecting availability of this nutrient to the neonate (9, 88). Changes in 
transporter expression has been shown to vary, following five key patterns, depending on the 
duration of lactation corresponding with the needs of the developing neonate at that time (9, 10). 
The varying expression of OCTNs allow for a greater drug-nutrient interaction involving L-
carnitine when OCTN expression levels are high, resulting in significant differences in milk-
serum ratios of L-carnitine as well as different consequences of a drug-nutrient transporter 
interaction (9). When mammary epithelial monolayers were challenged with inflammatory 
stimulus, an increase in maximal activity (Vmax) of L-carnitine transport without an effect on the 
affinity (Km) was noted. This corresponded to changes in cellular energy levels and oxygen 
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consumption rates (Uma Manthena MSc Thesis). Further, when the transporters were challenged 
with D-lactate, an inhibitor of transport by MCTs, a 75% reduction in cellular respiration was 
noted (88). As an extension to this, the premise of my work originally set out to focus on the 
impacts of pharmacological inhibition of nutrient transporters on the flux of essential nutrients as 
a proof of concept of the potential adverse effects related to nursing neonate when the lactating 
mother requires medication. 
Many interactions have been documented in the intestinal epithelium involving MCT1, 
which is of concern as this is the primary transporter of butyrate, the SCFA that represents 70% 
of the energy source for colonic cells (59, 64, 65, 67). The mammary gland primarily relies on 
glycolysis to supply its energy and, therefore, these two epithelial systems have differing energy 
sources (24). Due to the different energy requirement of the two systems, we looked at the 
effects transport inhibition of those nutrients involved in energy metabolism in hopes of adding 
to the lab’s accumulating evidence that pharmacological inhibition of nutrient transporters might 
represent an important toxicological mechanism in the nursing mother-neonate dyad. 
The Caco-2, (human colorectal adenocarcinoma) cell line was chosen to represent the 
neonatal intestinal epithelium. This cell line displays a number of properties characteristic of 
differentiated intestinal epithelial cells (89). Good correlation has been identified for absorption 
of drugs in human jejunum and Caco-2 cells, especially for passively absorbed drugs (90, 91). 
Further, various transporters (including MCT1 an OCTN2), enzymes, and nuclear receptors 
expressed in the in vivo intestinal epithelium are present in the Caco-2 cells (91).  These 
polarized epithelial cells have routinely been cultivated into polarized monolayers to study 
transepithelial transport of drugs across the intestinal epithelium, including studies done in our 
laboratory (83, 92). However, limitations and differences exist as this cell line is colorectal in 
nature and nutrient absorption typically occurs along the length of the small intestine. 
Furthermore, Caco-2 cells better represent the differentiated adult epithelium, while important 
differences in enzyme and transporter expression exist in the neonatal epithelium that often make 
extrapolation of information obtained in adult systems to the developing infant somewhat 
erroneous. For drugs absorbed primarily paracellularly or by transporters, the apparent 
permeability will be lower in Caco-2 cells due to narrower tight junctions and a reduced 
expression of absorptive transporters versus those found in the jejunum (91). Despite this, the use 
of the Caco-2 monolayer remains prevalent for permeability, transport, and metabolic studies due 
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to its well characterization and ability to maintain in culture (91). Therefore, we accepted the 
limitations and made use of the Caco-2 cell line to represent the neonatal intestinal epithelium in 
this proof of concept study. 
When studying the polarized mammary epithelium, few in vitro models are available and 
include the CIT 3/fibrocyte co-culture (murine model) (93) and Mac-T cells (bovine model) (94). 
Recently, research groups have shown success using the BME-UV cells to represent a polarized 
monolayer of the mammary epithelium and have shown this cell line expresses the functional 
transporters of interest (86, 87). Unfortunately, I encountered problems culturing the cell line 
into a polarized monolayer in our home laboratory. I attempted to optimize media pH, frequency 
of media change, cell seeding density, duration of growth period, and transwell diameter. Despite 
my troubleshooting efforts, reaching a TEER value above 300 Ω was inconsistent and LY yellow 
rejection rates peaked at 85%, a clear indication that the cells did not form a polarized 
monolayer. Inability to form a polarized epithelium is a problem for two reasons; 1) it is well 
known tight junctions regulate gene expression. Without proper tight junction formation the 
cellular phenotype is unlikely to mimic the lactating epithelium in vivo (95, 96); and 2) this 
precluded an assessment of nutrient flux since both paracellular and transcellular transport routes 
were available for nutrient transfer across the epithelium. Assessment of flux was a main 
objective of the project. This forced the project to focus on the indirect effects of 
pharmacological inhibition of the nutrient transporters on barrier integrity through a disruption in 
cellular homeostasis. 
The first step taken to evaluate the indirect effects was to assess barrier integrity by 
measuring TEER values and LY rejection rates. TEER measurements are used to measure the 
ion movement across the paracellular pathway of the epithelium and are used as an indirect 
assessment of tight junction establishment. LY is a substance that can only transverse the 
epithelium via the paracellular route, so similarly, it also depicts the ‘tightness’ of the tight 
junctions and integrity of the system. Their simultaneous measurement allows for a greater 
confidence in the determination of the integrity and polarization of the monolayer. On three 
separate occasions, cell lines were cultured for three weeks in 24 well transwells and exposed to 
IC50 values of known inhibitors to OCTN2, the high affinity transporter for L-carnitine uptake, 
and MCT1, the principle transporter involved in butyrate uptake, for 6, 12, and 24 hours as well 
as for 7 days, to represent acute and chronic inhibition, with TEER values and LY rejection rates 
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measured at each time point. No significant variation was noted between control and treatment 
groups in either cell line. One plausible explanation could be incomplete inhibition of the 
nutrient transport. While OCTN2 and MCT1 are high affinity L-carnitine and butyrate 
transporters, respectively, these nutrients are additionally transported by a variety of other 
transporters (9, 54, 82). The inhibitors chosen, verapamil and AR-C155858, were inhibitors 
specific of OCTN2 and MCT1, respectively. Therefore, L-carnitine and butyrate uptake into the 
epithelium may have been adequate to prevent any significant effects on barrier integrity. 
General inhibitors of L-carnitine and butyrate uptake transporters would be necessary to 
corroborate these suppositions, and further, to provide experimental support for the hypothesis. 
Chronic exposure to drugs that inhibit transporter function is known to cause alteration in 
the expression of transporters (97, 98). To assess alterations in transporter expression profiles 
with chronic exposure to specific inhibitors of OCTN2 and butyrate, cells assessed for of TEER 
and LY rejection rates were subsequently washed with phosphate buffered saline and Trizol was 
added to allow cell lysis to occur. The sample was then collected and stored at -80°C until RNA 
extraction. Sufficient RNA yields were a concern with the use of 24-well transwells due to their 
minimal growing surface area. The low RNA yields, which averaged around 50 ng/µL, was 
likely due to an inadequate surface area cell growth, although RNA degradation due to cell 
storage cannot be ruled out. To address the low RNA yield, I made use of the SuperScript VILO 
cDNA synthesis kit. This kit is quite sensitive and I omitted the option of performing a 20-fold 
dilution of the resulting cDNA in hopes of obtaining the maximum cDNA concentration from the 
RNA yield. Unfortunately, qPCR confirmed the low RNA yields as CT values of the internal 
control gene were quite high and the CT values of the target genes were insufficient to allow their 
quantification under the present qPCR cycle conditions. 
The second objective focused on the indirect effects of inhibition of L-carnitine and 
butyrate uptake on cellular homeostasis. Both L-carnitine and butyrate have key roles in the 
cellular energy metabolism and homeostasis. L-carnitine is essential for the utilization of long 
chain fatty acids (LCFAs) as it facilitates their transport into the mitochondrial matrix where the 
enzymes required for β-oxidation of LCFAs are located (69). Therefore, adequate concentrations 
of L-carnitine must exist in the tissues or β-oxidation will decrease and cellular energy 
metabolism will be impaired (69). Further, L-carnitine serves a key role in the activation of 
aerobic glycolysis, enhancement of respiratory chain function, donor of acetyl groups for 
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biosynthesis (e.g. acetyl choline), and membrane stabilization (68). Butyrate, acetate, and 
propionate, the predominant SCFAs, are absorbed readily by colonocytes and are used as the 
preferred source of fuel by these cells (75). Butyrate is oxidized more readily than propionate 
and acetate by colonocytes and its oxidation occurs regardless of the presence of other SCFAs 
(76). Due to this, β-oxidation of butyrate accounts for up to 70% of the totally energy consumed 
by the colonocytes (77). Due to the importance of these two nutrients in energy metabolism, any 
inhibition has the potential to alter cellular homeostasis resulting in disruption of the epithelial 
barrier. Further, adequate energy generation is critical to the maintenance of tight junction 
function (99). Therefore, inhibition of L-carnitine and/or butyrate can impact the integrity of the 
epithelium through either disruption of cellular homeostasis or through decreased tight junction 
function. 
To assess the effects of pharmacological inhibition of L-carnitine and butyrate 
transporters on cellular homeostasis, focus was given to ATP production, glycolysis rates, and 
cellular respiration as a combined measurement of these parameters allows a detailed metabolic 
assessment (100-102). The main energy producing pathways within a cell, including glycolysis 
and β-oxidation of fatty acids, work in concert to maintain optimal cellular energy status (100). 
ATP levels in healthy cells are, therefore, maintained at a constant level (usually around 1-10 
mM depending on the cell) (103). Parallel measurement of ECA fluxes and OCR, with 
measurement of ATP production, allows for a complete, systematic bioenergetics assessment 
within the cellular system (100). Three assays were selected; the CellTiter-Glo Luminescent Cell 
Viability Assay, the pH-Xtra Glycolysis Assay, and the MitoXpress Xtra Oxygen Consumption 
Assay to assess the above mentioned parameters, respectively.  
The CellTiter-Glo Luminescent Cell Viability Assay determines the number of viable 
cells based on ATP quantitation which is directly proportional to the luminescent signal. Cells 
were seeded and allowed to attach prior to their treatment for 6 hours with the IC50 value of the 
chosen inhibitors. No significant variation in ATP content was found between the treated and 
control groups in either cell lines. This could be due to an inadequate duration of treatment 
where the breakdown of barrier integrity takes place chronically and requires consistent 
disruption of cellular homeostasis (104). In order to perform chronic studies, the cells require 
frequent media changes to prevent apoptosis as well as daily treatment with the inhibitors. 
Unfortunately, this was not possible for this assay as it is performed in 96 well plates and the 
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possibility of disrupting the cells is too great. Another plausible explanation could be the 
adaptation of the cells to the inhibition of butyrate and L-carnitine uptake. Both of these nutrients 
are critical for the oxidation of the fatty acids; L-carnitine is responsible for the transport of the 
fatty acid into the mitochondrial matrix and butyrate is the primary SCFA oxidized for energy 
within the intestine. When inhibited, the cells must adapt and generate their energy through other 
means or else apoptosis will occur. Often, and in the case of the mammary and intestinal 
epithelium, the secondary means of energy metabolism is through glycolysis.  
 As lactate is the main contributor to ECA, measuring ECA is a convenient way to assess 
cellular glycolytic flux. The pH-Xtra Glycolysis Assay allows for the real time, kinetic analysis 
of ECA, thus giving an insight into glycolytic activity. Cells were seeded at 50,000 cells/well as 
the assay suggested this density would provide a suitable balance between ECA response and 
cell availability. Optional controls for this assay included a signal control, blank control, positive 
control (Antimycin A) and negative control (Oxamic Acid). The first three of the optional 
controls were utilized. Cells were allowed to attach overnight before being exposed to the 
inhibitors. Kinetic analysis of ECA was measured immediately for 120 minutes. In treatments 
with both verapamil and AR-C155858, an upward trend in glycolytic flux was noted in both the 
Caco-2 and BME cell lines. This is consistent with the expected results as both L-carnitine and 
butyrate are required for the β-oxidation of fatty acids in the production of energy. When 
inhibited, the cells adapt and switch to glycolysis in order to obtain the necessary energy. Cell 
survival is dependent on stimulating glucose oxidation, either directly or indirectly, when fatty 
acid oxidation is inhibited (105). Liepinsh et al. found a substantial increase in rate of glucose 
uptake when L-carnitine concentration was reduced by mildronate treatment and suggested that 
the change in glucose metabolism represented a compensatory role (106). It was expected, 
however, to have seen a greater increase in glycolysis in the Caco-2 cell line as the intestinal 
epithelium relies on β-oxidation of fatty acids as its preferred energy source, while the mammary 
epithelium relies on glycolysis. This could be explained by incomplete inhibition of the MCT1 
transporter resulting in continued fatty acid oxidation as an energy source. Use of the negative 
control would have provided further insight towards this as the level of increased glycolytic flux 
we observed could have been compared to the negative response. This would have confirmed the 
response we were seeing as, in fact, an upward trend. 
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 The MitoXpress Oxygen Consumption Assay allows for the kinetic analysis of cellular 
respiration by measuring extracellular oxygen consumption. Optional controls for this assay 
included a signal control, blank control, negative control (Antimycin A) and positive control 
(Glucose Oxidase). The first three of the optional controls were utilized. Cells were allowed to 
attach overnight before being exposed to the inhibitors. Kinetic analysis of OCR was measured 
immediately for 120 minutes. In treatments with both verapamil and AR-C155858, an upward 
trend in cellular respiration was noted in both the Caco-2 and BME cell lines. With an increase in 
glycolysis, one would expect to see a decrease in oxygen consumption. Alcorn et al found up to a 
75% reduction in respiration in the presence of D-lactate, an inhibitor of transport by MCTs (88). 
L-Lactate, when transported into the mitochondria by MCTs, is metabolized to pyruvate for 
energy metabolism (88). Similar findings should have been noted with the inhibition of MCT 
transport of butyrate; however, we noted an upward trend in respiration. One explanation to this 
increase could be the production of reactive oxygen species (ROS). Neutrophils, in particular, 
have been shown to undergo a ‘respiratory burst’ and generate substantial amounts of ROS under 
numerous circumstances including transporter inhibition (107). This occurs through activation of 
the NADPH-oxidase system, which in turn, catalyzes oxygen molecules to form superoxide 
anions during non-mitochondria oxygen uptake (107). These reactive oxidant superoxides are 
then converted to hydrogen peroxide which is metabolized into oxygen and water, oxidized 
glutathione and water, or the more potent hydroxyl radicals  (107). The superoxides as well as 
the radicals can both elucidate an inflammatory response as well as mediate cell death (107). 
Maintaining a high butyrate concentration in the colon has been related to a reduction in ROS-
induced injury of colonocytes (107). Therefore, inhibition of MCT1, the main transporter of 
butyrate, could potentially lead to an increase in ROS production resulting in an increase in 
oxygen consumptions noted in our experiments. 
In summary, our study attempted to provide a proof-of-concept for the ability of drug-
nutrient transporter interactions at mammary and intestinal epithelia to directly and indirectly 
affect the developing neonate. Inhibition of the flux of essential nutrients across the barrier may 
result in a decrease in the availability of these key components that are essential for proper 
growth and maturation of the developing neonate. Due to the importance of these nutrients on 
epithelial cellular energy metabolism this, indirectly, has the ability to disrupt barrier integrity 
through a loss of cellular homeostasis. Epithelial dysfunction may lead to adverse effects on the 
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neonate. Complications in obtaining a polarized mammary monolayer forced my thesis work to 
focus on the indirect affects which were measured by assessing barrier integrity and cellular 
homeostasis. No change was noted upon treatment with MCT1 and OCTN2 inhibitors on TEER 
values, LY rejection rates, or ATP production. Upward trends were noted in treatment groups in 
glycolytic flux and oxygen consumption in both cell lines. Overall, pharmacological inhibition of 
the high affinity transporters of L-carnitine and butyrate had no significant effect on epithelial 
cellular functions as reflected through glycolytic flux, oxygen consumption rates, and ATP 
production. 
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6. FUTURE WORK 
 
A main focus of this study was the assessment of the direct effects of pharmacological 
inhibition of nutrient transporters at the mammary and intestinal epithelium on nutrient flux and 
the indirect effect of inhibition on the integrity of these polarized epithelia. To assess this, it was 
critical to achieve a polarized monolayer of both systems to allow for the comparison between 
the mammary and intestinal epithelia. Unfortunately, this was not achieved with the 
experimental system chosen to represent the mammary epithelium, the BME-UV cell line, 
despite literature evidence to the contrary. Obtaining and validating a polarized mammary 
epithelium is critical in advancing our understanding of the direct and indirect effects of 
pharmacological inhibition of nutrient transporters on nutrient flux and epithelial barrier 
function. 
Challenges exist when selecting an in vitro system to represent the mammary and 
intestinal polarized epithelia. Few in vitro models exist although significant recent advances in 
alternate experimental systems such as tissue explants, 3D cultures, organoids, and primary 
epithelial cells, make such systems an attractive alternative to assess my research hypotheses. 
These alternative systems warrant attention as the currently used, 2D filter insert culture system 
is expensive, laborious and requires large numbers of cells per sample. Further, they fail to 
accurately represent the complex and active nature of the mammary and intestinal epitheliums 
that exist in vivo. 
In particular, future studies should make use of 3D cultures (possibly those created from 
primary epithelial cells) to represent the mammary and intestinal epithelia. Such 3D culture 
systems have drastically evolved since their conception and continue to undergo important 
refinements that aim to ultimately recreate the organ in culture (108). Furthermore, it will 
potentially allow investigations pertaining to particular development stages and environmental 
constraints that exist in the in vivo system (108). This is of particular importance when 
examining dynamic systems such as that of the lactating mammary and neonatal intestinal 
epithelia as both go under a great amount of growth and differentiation over time.  
To set up a 3D culture, the epithelial cells are cultured inside Laminin-Rich Extracellular 
Matrix (lrECM) such that they are fully surrounded by an lrECM thick coat (108). Biochemical 
analysis, including RNA profiling and quantitation as well as protein analysis, is possible with 
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3D cultures and is usually done by solubilizing the gels using ECM-specific proteases (ex: PBS-
EDTA) (108). The extracted cells are then subjected to the protocols normally made use of for 
RNA extraction and isolation. This not only allows insight into transporter expression, but can 
also be used to assess the proteins associated with tight junction formation.  Tight junctions are 
integrated by numerous proteins including occludin, tricellulin, claudins and JAMS which 
represent the integral proteins and are all responsible for paracellular ionic selectivity (95). 
Further proteins, the adapter proteins, include ZOs, MAGIs, cingulin and paracingulin and 
function as the bridge between the integral proteins and the actin cytoskeleton (95).  Tight 
junction formation is critical for barrier integrity, cellular energy metabolism and gene 
expression; therefore, assessing the quantitation of the proteins involved in tight junction 
formation allows insight into the effects of pharmacological inhibition of nutrient transporters 
on epithelial function (104). 
One of the most critical studies when assessing pharmacological inhibition of transporters 
is looking at the flux of the nutrients associated with the transporters you are inhibiting. This is 
challenging due to the time dependence of such studies, in particular, with butyrate as it is 
oxidized in the system so readily. However, these studies are invaluable when assessing the 
direct effects of nutrient transporter inhibition. Radiolabeled tracers can provide insightful 
information on the flux distributions within biological samples. Intracellular fluxes can be 
directly determined from the radioactivity count data by tracking the depletion of the 
radiolabeled metabolite and/or the accompanying accumulation of any products formed (109). 
For example, 
13
C-labelling can yield flux information within bacterial cultures, mammalian cell 
culture, organ tissues and erythrocytes (109).  By assessing the flux of the nutrients involved in 
energy metabolism, it allows insight on the degree of pharmacological inhibition and the direct 
effects of such inhibition on the cell. 
In summary, obtaining and utilizing a more accurate portrayal of the lactating mammary 
and neonatal intestinal epithelium is critical in answering this research question. 3D cultures 
provide promise for this as they allow investigations pertaining to particular development stages 
and environmental constraints, which is critical when examining the two epithelial systems. 
Assessment of the flux of the essential nutrients is key to understanding the direct effects of 
pharmacological inhibition of transporters. Finally, assessment of the alterations of tight 
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junction function following nutrient transporter inhibition warrant attentions as tight junctions 
are critical for barrier integrity, cellular homeostasis, and gene expression. 
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